Published in Hum Mol Genet on November 18, 2010
When lamins go bad: nuclear structure and disease. Cell (2013) 1.84
The nuclear lamins: flexibility in function. Nat Rev Mol Cell Biol (2012) 1.76
Nuclear lamin functions and disease. Trends Genet (2012) 1.52
Depleting the methyltransferase Suv39h1 improves DNA repair and extends lifespan in a progeria mouse model. Nat Commun (2013) 1.12
Human ZMPSTE24 disease mutations: residual proteolytic activity correlates with disease severity. Hum Mol Genet (2012) 1.11
Inner nuclear membrane proteins: impact on human disease. Chromosoma (2012) 1.05
Farnesyltransferase inhibitor treatment restores chromosome territory positions and active chromosome dynamics in Hutchinson-Gilford progeria syndrome cells. Genome Biol (2011) 0.96
Understanding the roles of nuclear A- and B-type lamins in brain development. J Biol Chem (2012) 0.93
Blocking farnesylation of the prelamin A variant in Hutchinson-Gilford progeria syndrome alters the distribution of A-type lamins. Nucleus (2012) 0.90
Disruption of lamin B1 and lamin B2 processing and localization by farnesyltransferase inhibitors. Nucleus (2013) 0.90
Efficient use of exogenous isoprenols for protein isoprenylation by MDA-MB-231 cells is regulated independently of the mevalonate pathway. J Biol Chem (2013) 0.88
Mutant lamin A links prophase to a p53 independent senescence program. Cell Cycle (2015) 0.88
Structure and stability of the lamin A tail domain and HGPS mutant. J Struct Biol (2011) 0.87
Potential therapeutic approaches for modulating expression and accumulation of defective lamin A in laminopathies and age-related diseases. J Mol Med (Berl) (2012) 0.87
Preventing farnesylation of the dynein adaptor Spindly contributes to the mitotic defects caused by farnesyltransferase inhibitors. Mol Biol Cell (2015) 0.86
Molecular insights into the premature aging disease progeria. Histochem Cell Biol (2016) 0.86
Protein prenylation: unique fats make their mark on biology. Nat Rev Mol Cell Biol (2016) 0.85
Targeting protein prenylation in progeria. Sci Transl Med (2013) 0.85
DNA-damage accumulation and replicative arrest in Hutchinson-Gilford progeria syndrome. Biochem Soc Trans (2011) 0.84
Neonatal progeria: increased ratio of progerin to lamin A leads to progeria of the newborn. Eur J Hum Genet (2012) 0.83
Nuclear localization signal deletion mutants of lamin A and progerin reveal insights into lamin A processing and emerin targeting. Nucleus (2014) 0.78
HP1α mediates defective heterochromatin repair and accelerates senescence in Zmpste24-deficient cells. Cell Cycle (2014) 0.78
iTRAQ-based analysis of progerin expression reveals mitochondrial dysfunction, reactive oxygen species accumulation and altered proteostasis. Stem Cell Res Ther (2015) 0.77
An encouraging progress report on the treatment of progeria and its implications for atherogenesis. Circulation (2014) 0.77
Recurrent de novo point mutations in lamin A cause Hutchinson-Gilford progeria syndrome. Nature (2003) 12.10
Lamin a truncation in Hutchinson-Gilford progeria. Science (2003) 8.01
Life at the edge: the nuclear envelope and human disease. Nat Rev Mol Cell Biol (2002) 3.84
Defective prelamin A processing and muscular and adipocyte alterations in Zmpste24 metalloproteinase-deficient mice. Nat Genet (2002) 3.78
Inhibiting farnesylation of progerin prevents the characteristic nuclear blebbing of Hutchinson-Gilford progeria syndrome. Proc Natl Acad Sci U S A (2005) 3.64
"Laminopathies": a wide spectrum of human diseases. Exp Cell Res (2007) 3.46
Combined treatment with statins and aminobisphosphonates extends longevity in a mouse model of human premature aging. Nat Med (2008) 3.34
Blocking protein farnesyltransferase improves nuclear blebbing in mouse fibroblasts with a targeted Hutchinson-Gilford progeria syndrome mutation. Proc Natl Acad Sci U S A (2005) 3.30
Zmpste24 deficiency in mice causes spontaneous bone fractures, muscle weakness, and a prelamin A processing defect. Proc Natl Acad Sci U S A (2002) 3.26
Prelamin A, Zmpste24, misshapen cell nuclei, and progeria--new evidence suggesting that protein farnesylation could be important for disease pathogenesis. J Lipid Res (2005) 2.88
Blocking protein farnesyltransferase improves nuclear shape in fibroblasts from humans with progeroid syndromes. Proc Natl Acad Sci U S A (2005) 2.85
A protein farnesyltransferase inhibitor ameliorates disease in a mouse model of progeria. Science (2006) 2.71
Incomplete processing of mutant lamin A in Hutchinson-Gilford progeria leads to nuclear abnormalities, which are reversed by farnesyltransferase inhibition. Hum Mol Genet (2005) 2.69
Werner and Hutchinson-Gilford progeria syndromes: mechanistic basis of human progeroid diseases. Nat Rev Mol Cell Biol (2007) 2.56
A farnesyltransferase inhibitor improves disease phenotypes in mice with a Hutchinson-Gilford progeria syndrome mutation. J Clin Invest (2006) 2.39
Heterozygosity for Lmna deficiency eliminates the progeria-like phenotypes in Zmpste24-deficient mice. Proc Natl Acad Sci U S A (2004) 2.39
Zinc metalloproteinase, ZMPSTE24, is mutated in mandibuloacral dysplasia. Hum Mol Genet (2003) 2.36
Alterations in mitosis and cell cycle progression caused by a mutant lamin A known to accelerate human aging. Proc Natl Acad Sci U S A (2007) 2.24
Prelamin A and lamin A appear to be dispensable in the nuclear lamina. J Clin Invest (2006) 2.23
Loss of ZMPSTE24 (FACE-1) causes autosomal recessive restrictive dermopathy and accumulation of Lamin A precursors. Hum Mol Genet (2005) 2.06
Homozygous and compound heterozygous mutations in ZMPSTE24 cause the laminopathy restrictive dermopathy. J Invest Dermatol (2005) 2.06
Inhibiting farnesylation reverses the nuclear morphology defect in a HeLa cell model for Hutchinson-Gilford progeria syndrome. Proc Natl Acad Sci U S A (2005) 2.05
Disruption of the mouse Rce1 gene results in defective Ras processing and mislocalization of Ras within cells. J Biol Chem (1999) 1.90
Disease progression in Hutchinson-Gilford progeria syndrome: impact on growth and development. Pediatrics (2007) 1.67
Biochemical studies of Zmpste24-deficient mice. J Biol Chem (2001) 1.61
New approaches to progeria. Pediatrics (2007) 1.47
Prelamin A farnesylation and progeroid syndromes. J Biol Chem (2006) 1.43
Progerin elicits disease phenotypes of progeria in mice whether or not it is farnesylated. J Clin Invest (2008) 1.40
Tools to analyze protein farnesylation in cells. Bioconjug Chem (2005) 1.35
Treatment with a farnesyltransferase inhibitor improves survival in mice with a Hutchinson-Gilford progeria syndrome mutation. Biochim Biophys Acta (2007) 1.33
The nuclear envelope and human disease. Physiology (Bethesda) (2004) 1.32
The A-type lamins: nuclear structural proteins as a focus for muscular dystrophy and cardiovascular diseases. Trends Cardiovasc Med (2001) 1.28
An accumulation of non-farnesylated prelamin A causes cardiomyopathy but not progeria. Hum Mol Genet (2010) 1.26
Compound heterozygous ZMPSTE24 mutations reduce prelamin A processing and result in a severe progeroid phenotype. J Med Genet (2005) 1.25
Direct synthesis of lamin A, bypassing prelamin a processing, causes misshapen nuclei in fibroblasts but no detectable pathology in mice. J Biol Chem (2010) 1.24
A homozygous ZMPSTE24 null mutation in combination with a heterozygous mutation in the LMNA gene causes Hutchinson-Gilford progeria syndrome (HGPS): insights into the pathophysiology of HGPS. Hum Mutat (2006) 1.20
Genetic studies on the functional relevance of the protein prenyltransferases in skin keratinocytes. Hum Mol Genet (2010) 1.13
Mutation analysis of the lamin A/C gene (LMNA) among patients with different cardiomuscular phenotypes. J Med Genet (2003) 1.13
Compound heterozygosity for mutations in LMNA causes a progeria syndrome without prelamin A accumulation. Hum Mol Genet (2006) 1.11
Expression systems for nuclear lamin proteins: farnesylation in assembly of nuclear lamina. Methods Enzymol (1995) 1.04
Protein farnesyltransferase inhibitors and progeria. Trends Mol Med (2006) 1.02
Assessing the efficacy of protein farnesyltransferase inhibitors in mouse models of progeria. J Lipid Res (2009) 1.01
A potent HIV protease inhibitor, darunavir, does not inhibit ZMPSTE24 or lead to an accumulation of farnesyl-prelamin A in cells. J Biol Chem (2008) 0.99
p.S143F mutation in lamin A/C: a new phenotype combining myopathy and progeria. Ann Neurol (2005) 0.96
The knockout mouse project. Nat Genet (2004) 7.80
Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy. Nat Med (2005) 6.50
Glycosylphosphatidylinositol-anchored high-density lipoprotein-binding protein 1 plays a critical role in the lipolytic processing of chylomicrons. Cell Metab (2007) 5.04
BayGenomics: a resource of insertional mutations in mouse embryonic stem cells. Nucleic Acids Res (2003) 4.83
A public gene trap resource for mouse functional genomics. Nat Genet (2004) 3.96
p38 MAP kinase inhibition enables proliferation of adult mammalian cardiomyocytes. Genes Dev (2005) 3.88
Linking lipid metabolism to the innate immune response in macrophages through sterol regulatory element binding protein-1a. Cell Metab (2011) 3.49
The International Gene Trap Consortium Website: a portal to all publicly available gene trap cell lines in mouse. Nucleic Acids Res (2006) 3.40
Blocking protein farnesyltransferase improves nuclear blebbing in mouse fibroblasts with a targeted Hutchinson-Gilford progeria syndrome mutation. Proc Natl Acad Sci U S A (2005) 3.30
ESCRT-III dysfunction causes autophagosome accumulation and neurodegeneration. Curr Biol (2007) 3.27
Zmpste24 deficiency in mice causes spontaneous bone fractures, muscle weakness, and a prelamin A processing defect. Proc Natl Acad Sci U S A (2002) 3.26
Oxidant stress from nitric oxide synthase-3 uncoupling stimulates cardiac pathologic remodeling from chronic pressure load. J Clin Invest (2005) 3.22
Cholesterol-induced macrophage apoptosis requires ER stress pathways and engagement of the type A scavenger receptor. J Cell Biol (2005) 3.14
Lamins A and C but not lamin B1 regulate nuclear mechanics. J Biol Chem (2006) 3.02
Chylomicronemia with a mutant GPIHBP1 (Q115P) that cannot bind lipoprotein lipase. Arterioscler Thromb Vasc Biol (2009) 2.99
Laminopathies and the long strange trip from basic cell biology to therapy. J Clin Invest (2009) 2.94
Lamin B1 is required for mouse development and nuclear integrity. Proc Natl Acad Sci U S A (2004) 2.89
Prelamin A, Zmpste24, misshapen cell nuclei, and progeria--new evidence suggesting that protein farnesylation could be important for disease pathogenesis. J Lipid Res (2005) 2.88
Blocking protein farnesyltransferase improves nuclear shape in fibroblasts from humans with progeroid syndromes. Proc Natl Acad Sci U S A (2005) 2.85
GPIHBP1 is responsible for the entry of lipoprotein lipase into capillaries. Cell Metab (2010) 2.75
A protein farnesyltransferase inhibitor ameliorates disease in a mouse model of progeria. Science (2006) 2.71
Mitogen-activated protein kinase signaling in the heart: angels versus demons in a heart-breaking tale. Physiol Rev (2010) 2.68
A farnesyltransferase inhibitor improves disease phenotypes in mice with a Hutchinson-Gilford progeria syndrome mutation. J Clin Invest (2006) 2.39
Heterozygosity for Lmna deficiency eliminates the progeria-like phenotypes in Zmpste24-deficient mice. Proc Natl Acad Sci U S A (2004) 2.39
Chronic suppression of heart-failure progression by a pseudophosphorylated mutant of phospholamban via in vivo cardiac rAAV gene delivery. Nat Med (2002) 2.37
Alterations in mitosis and cell cycle progression caused by a mutant lamin A known to accelerate human aging. Proc Natl Acad Sci U S A (2007) 2.24
Prelamin A and lamin A appear to be dispensable in the nuclear lamina. J Clin Invest (2006) 2.23
Lowering plasma cholesterol levels halts progression of aortic valve disease in mice. Circulation (2009) 2.20
Calcific aortic valve stenosis in old hypercholesterolemic mice. Circulation (2006) 2.13
c-Jun N-terminal kinase activation mediates downregulation of connexin43 in cardiomyocytes. Circ Res (2002) 2.11
GPIHBP1: an endothelial cell molecule important for the lipolytic processing of chylomicrons. Curr Opin Lipidol (2007) 2.01
Sustained activation of JNK/p38 MAPK pathways in response to cisplatin leads to Fas ligand induction and cell death in ovarian carcinoma cells. J Biol Chem (2003) 1.95
Blocking VLDL secretion causes hepatic steatosis but does not affect peripheral lipid stores or insulin sensitivity in mice. J Lipid Res (2008) 1.91
The acidic domain of GPIHBP1 is important for the binding of lipoprotein lipase and chylomicrons. J Biol Chem (2008) 1.91
Functional coupling between the extracellular matrix and nuclear lamina by Wnt signaling in progeria. Dev Cell (2010) 1.90
Abnormal development of the cerebral cortex and cerebellum in the setting of lamin B2 deficiency. Proc Natl Acad Sci U S A (2010) 1.89
Targeting isoprenylcysteine methylation ameliorates disease in a mouse model of progeria. Science (2013) 1.88
Deficiencies in lamin B1 and lamin B2 cause neurodevelopmental defects and distinct nuclear shape abnormalities in neurons. Mol Biol Cell (2011) 1.86
Postprenylation CAAX processing is required for proper localization of Ras but not Rho GTPases. Mol Biol Cell (2005) 1.85
Macrophage deficiency of p38alpha MAPK promotes apoptosis and plaque necrosis in advanced atherosclerotic lesions in mice. J Clin Invest (2009) 1.83
The posttranslational processing of prelamin A and disease. Annu Rev Genomics Hum Genet (2009) 1.81
Inactivation of Icmt inhibits transformation by oncogenic K-Ras and B-Raf. J Clin Invest (2004) 1.81
Reversal of hyperlipidemia with a genetic switch favorably affects the content and inflammatory state of macrophages in atherosclerotic plaques. Circulation (2011) 1.79
Regulation of voltage-gated calcium channel activity by the Rem and Rad GTPases. Proc Natl Acad Sci U S A (2003) 1.74
Myocardin induces cardiomyocyte hypertrophy. Circ Res (2006) 1.74
Abnormal patterns of lipoprotein lipase release into the plasma in GPIHBP1-deficient mice. J Biol Chem (2008) 1.73
Chylomicronemia elicits atherosclerosis in mice--brief report. Arterioscler Thromb Vasc Biol (2009) 1.72
Moderate heart dysfunction in mice with inducible cardiomyocyte-specific excision of the Serca2 gene. J Mol Cell Cardiol (2009) 1.72
The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single-dose administration in type 2 diabetic patients. J Clin Endocrinol Metab (2007) 1.70
Divergent mitochondrial biogenesis responses in human cardiomyopathy. Circulation (2013) 1.69
Junctophilin type 2 is associated with caveolin-3 and is down-regulated in the hypertrophic and dilated cardiomyopathies. Biochem Biophys Res Commun (2004) 1.69
Macrophage deletion of p38alpha partially impairs lipopolysaccharide-induced cellular activation. J Immunol (2008) 1.68
Agpat6 deficiency causes subdermal lipodystrophy and resistance to obesity. J Lipid Res (2006) 1.68
Eliminating atherogenesis in mice by switching off hepatic lipoprotein secretion. Circulation (2003) 1.68
Mutation of conserved cysteines in the Ly6 domain of GPIHBP1 in familial chylomicronemia. J Lipid Res (2009) 1.67
Myocardial remodeling is controlled by myocyte-targeted gene regulation of phosphodiesterase type 5. J Am Coll Cardiol (2010) 1.65
Differential membrane localization of ERas and Rheb, two Ras-related proteins involved in the phosphatidylinositol 3-kinase/mTOR pathway. J Biol Chem (2005) 1.64
Agpat6--a novel lipid biosynthetic gene required for triacylglycerol production in mammary epithelium. J Lipid Res (2006) 1.62
The role of the Grb2-p38 MAPK signaling pathway in cardiac hypertrophy and fibrosis. J Clin Invest (2003) 1.61
Chylomicronemia with low postheparin lipoprotein lipase levels in the setting of GPIHBP1 defects. Circ Cardiovasc Genet (2010) 1.60
Stat5a is tyrosine phosphorylated and nuclear localized in a high proportion of human breast cancers. Int J Cancer (2004) 1.60
A small-molecule inhibitor of isoprenylcysteine carboxyl methyltransferase with antitumor activity in cancer cells. Proc Natl Acad Sci U S A (2005) 1.59
Apobec-1 protects intestine from radiation injury through posttranscriptional regulation of cyclooxygenase-2 expression. Gastroenterology (2004) 1.56
Absence of the CAAX endoprotease Rce1: effects on cell growth and transformation. Mol Cell Biol (2002) 1.56
FTY720: placebo-controlled study of the effect on cardiac rate and rhythm in healthy subjects. J Clin Pharmacol (2006) 1.56
Highly conserved cysteines within the Ly6 domain of GPIHBP1 are crucial for the binding of lipoprotein lipase. J Biol Chem (2009) 1.54
Free cholesterol accumulation in macrophage membranes activates Toll-like receptors and p38 mitogen-activated protein kinase and induces cathepsin K. Circ Res (2009) 1.52
Nitric oxide donors protect murine myocardium against infarction via modulation of mitochondrial permeability transition. Am J Physiol Heart Circ Physiol (2004) 1.51
AGPAT6 is a novel microsomal glycerol-3-phosphate acyltransferase. J Biol Chem (2008) 1.50
Lack of p38 MAP kinase activation in TRAIL-resistant cells is not related to the resistance to TRAIL-mediated cell death. Cancer Biol Ther (2004) 1.49
CD1d function is regulated by microsomal triglyceride transfer protein. Nat Med (2004) 1.49
A novel mitochondrial matrix serine/threonine protein phosphatase regulates the mitochondria permeability transition pore and is essential for cellular survival and development. Genes Dev (2007) 1.49
Molecular and functional signature of heart hypertrophy during pregnancy. Circ Res (2005) 1.48
Disruption of the phosphatidylserine decarboxylase gene in mice causes embryonic lethality and mitochondrial defects. J Biol Chem (2005) 1.48
p38-MAPK induced dephosphorylation of alpha-tropomyosin is associated with depression of myocardial sarcomeric tension and ATPase activity. Circ Res (2007) 1.48